Clinical trials in patients with biochemically relapsed prostate cancer.

about

Clinical trials in patients with biochemically relapsed prostate cancer.

Item

http://www.wikidata.org/entity/Q36462096

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Clinical trials in patients with biochemically relapsed prostate cancer.

@ast

Clinical trials in patients with biochemically relapsed prostate cancer.

@en

type

Item

label

Clinical trials in patients with biochemically relapsed prostate cancer.

@ast

Clinical trials in patients with biochemically relapsed prostate cancer.

@en

prefLabel

Clinical trials in patients with biochemically relapsed prostate cancer.

@ast

Clinical trials in patients with biochemically relapsed prostate cancer.

@en

P1476

Clinical trials in patients with biochemically relapsed prostate cancer.

@en

P2093

Amy M Lin

http://www.w3.org/2001/XMLSchema#string

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Eric J Small

http://www.w3.org/2001/XMLSchema#string

P2860

Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects.

Natural history of progression after PSA elevation following radical prostatectomy.

Prostate specific antigen only progression of prostate cancer.

Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy.

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy.

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.

Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer.

Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results.

Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.

P304

905-910

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1464-410X.2006.06124.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16643469

http://www.w3.org/2001/XMLSchema#string